Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03465592 · ClinicalTrials.gov registry record · Phase 1

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

A Phase 1 study of Sarcoma and Solid Tumor, Adult, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Recruiting
Registry status
Phase 1
Development phase
39
Enrollment target
4
Study locations

NCT03465592 is a Phase 1 study of Sarcoma and Solid Tumor, Adult that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 39 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03465592, a Phase 1 study of Sarcoma and Solid Tumor, Adult, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

RECRUITING
Registry status
Phase 1
Development phase
39 participants
Enrollment target
4
Study locations

Study Summary

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow transplant and have either relapsed or are at high risk to relapse.

Conditions Studied

Sarcoma Solid Tumor, Adult Solid Tumor, Childhood

Interventions

  • DRUG Nivolumab

Study Locations (4)

New York

  • Albert Einstein College of Medicine, Children's Hospital at Montefiore - The Bronx
  • New York Medical Center/ Maria Fareri Children's Hospital - Valhalla

Florida

  • Johns Hopkins All Children's Hospital - St. Petersburg

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2018-05-01
Est. Completion 2029-03
Phase Phase 1

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03465592

The ClinicalTrials.gov registry entry for NCT03465592 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.

NCT03465592 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT03465592 about?

NCT03465592 is a clinical study titled "Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma". This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will al...

What is the current status of trial NCT03465592?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2018-05-01. Estimated completion is 2029-03.

What conditions does trial NCT03465592 study?

This clinical trial studies the following conditions: Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood.

What interventions are being tested in trial NCT03465592?

The interventions under investigation include: Nivolumab (DRUG).

Who is sponsoring clinical trial NCT03465592?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03465592 being conducted?

This trial has 4 study locations across Florida, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Solid Tumor, Adult

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.